NCT05916092

Brief Summary

A prospective study on the use of the TransLoc 3D SI Joint Fusion System for patients with sacroiliac joint disruptions or degenerative sacroiliitis.

Trial Health

75
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
240

participants targeted

Target at P75+ for all trials

Timeline
2mo left

Started Oct 2023

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
enrolling by invitation

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress94%
Oct 2023Jul 2026

First Submitted

Initial submission to the registry

June 13, 2023

Completed
10 days until next milestone

First Posted

Study publicly available on registry

June 23, 2023

Completed
4 months until next milestone

Study Start

First participant enrolled

October 19, 2023

Completed
2.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2025

Completed
7 months until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2026

Expected
Last Updated

February 6, 2024

Status Verified

February 1, 2024

Enrollment Period

2.1 years

First QC Date

June 13, 2023

Last Update Submit

February 5, 2024

Conditions

Outcome Measures

Primary Outcomes (2)

  • Clinical improvement at 12 months defined by a composite score of functional status, pain, and safety events.

    Functional improvement and pain score have long been the standard for SI joint improvement measures. Multiple functional improvement scales will be assessed throughout the study.

    12 months

  • Absence of Serious Adverse Events (SAEs)

    Demonstrate safety as defined by Serious Adverse Events (SAEs).

    From the time informed consent is signed through 12 months.

Secondary Outcomes (1)

  • Absence of study-related adverse events

    6 months, 12 months

Study Arms (2)

Lateral-Oblique TransLoc 3D Screw(s)

Patients receiving the TransLoc 3D Screw(s) version will receive screw(s) placed lateral-obliquely into the intended SI joint.

Device: TransLoc 3D

Lateral Oblique TransLoc 3D Screw with Posterior Device (Hybrid)

Patients receiving the TransLoc 3D Hybrid construct will receive one 3D-printed titanium screw placed lateral-obliquely and one 3D-printed titanium posterior device across the same sacroiliac joint.

Device: TransLoc 3D

Interventions

TransLoc 3D SI Joint Fusion System

Lateral Oblique TransLoc 3D Screw with Posterior Device (Hybrid)Lateral-Oblique TransLoc 3D Screw(s)

Eligibility Criteria

Age18 Years - 85 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Consecutive enrollment of all patients within inclusion criteria.

You may qualify if:

  • Age 18-85\* (\*Over 85 is allowed with H\&P assessment screening upon approval by Medical Monitor);
  • Absent condition of high-risk surgical candidate (see training manual for definition);
  • Patient has lower back pain with a confirmed diagnosis of sacroiliac joint disruption or degenerative sacroiliitis for a period of \>6 months and who has not responded to optimal conservative care (PT or prescribed HEP, optimal medical management including NSAIDs);
  • Diagnosis of sacroiliac joint disruption or degenerative sacroiliitis based on ALL of the following: a. Patient has pain at or close to the posterior superior iliac spine (PSIS) with possible radiation into buttocks, posterior thigh or groin and can point with a single finger to the location of pain (Fortin Finger Test), and b. at least three positive findings with provocative maneuvers (FABER, Gaenslen, Thigh Thrust or Posterior Shear, SI Compression, SI Distraction, and Yeoman Test);
  • Patient has a diagnostic SIJ injection (SIJI) that provided a minimum of 75% relief of primary (index) pain with the diagnostic SIJI on two separate occasions;
  • Patient meets Medicare and payer requirements for medical necessity, see detailed requirements in training manual;
  • SI joint disruption: Asymmetric SI joint widening on X-ray or CT scan or degenerative sacroiliitis with radiographic evidence of SIJ degeneration as evidenced on CT or X-ray;
  • SI joint pain or instability with or without prior lumbar/lumbosacral surgery;
  • Baseline Oswestry Disability Index (ODI) score of at least 30%;
  • Baseline SI joint pain score of at least 60 on 0-100mm visual analog scale (or at least a 6 on NRS);
  • Patient has the necessary mental capacity to participate and is physically able to comply with study protocol requirements;
  • Patient must be able to communicate with study personnel via phone, text, or email;
  • PI must confirm women of childbearing years are not pregnant or plan to become pregnant prior to surgery;
  • Cardiac Clearance for patients with diagnosis of cardiac disease;
  • Patient has signed study-specific informed consent form.

You may not qualify if:

  • Patient will not be entered into the study if they meet one of the following criteria:
  • Current severe back pain due to other causes, such as lumbar disc degeneration, lumbar disc herniation, lumbar spondylolisthesis, lumbar spinal stenosis, lumbar facet degeneration, lumbar radicular pain that extends beyond the mid-thigh, and lumbar vertebral body fracture;
  • SIJ pain secondary to inflammatory conditions or other known sacroiliac pathology such as: Sacral dysplasia, Inflammatory sacroiliitis (e.g., ankylosing spondylitis or other HLA-associated spondylo-arthropathy), Tumor or infection in the SI joint, Acute fracture or Crystal arthropathy;
  • History of recent (\<1 year) major trauma to pelvis (MVA or significant accident that results in acute injury to pelvis requiring hospitalization or surgery);
  • Previously diagnosed osteoporosis (defined as prior T-score \<-2.5 or history of osteoporotic fracture). If patient meets the osteoporosis screening criteria identified by the National Osteoporosis Foundation, they should be screened for osteoporosis with DEXA;
  • Autoimmune - patient who is currently not maintained on a medication regimen for treatment, and not stable (\<6 months without exacerbation);
  • Any condition or anatomy that makes treatment with the TransLoc 3D Sacroiliac Joint Fusion System infeasible;
  • Current local or systemic infection that raises the risk of surgery;
  • Patient currently receiving disability remuneration, and/or involved in injury litigation;
  • Patient is undergoing treatment under Workman's Compensation under a claim or injury greater than 1 year;
  • Patient is participating in an investigational study or has been involved in an investigational study within 3 months prior to evaluation for participation;
  • Known to be pregnant, suspected pregnant, or planning to be pregnant prior to SIJ surgery;
  • Patient is a prisoner or a ward of the state;
  • Known or suspected drug or alcohol abuse;
  • Known allergy to titanium or titanium alloys;
  • +1 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

NY Spine and Pain Specialists

Port Jefferson Station, New York, 11776, United States

Location

MeSH Terms

Conditions

Sacroiliitis

Condition Hierarchy (Ancestors)

ArthritisJoint DiseasesMusculoskeletal Diseases

Study Officials

  • Samuel Brown, DO

    NY Spine and Pain Specialists

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 13, 2023

First Posted

June 23, 2023

Study Start

October 19, 2023

Primary Completion

December 1, 2025

Study Completion (Estimated)

July 1, 2026

Last Updated

February 6, 2024

Record last verified: 2024-02

Data Sharing

IPD Sharing
Will not share

Locations